RenovoRx Inc - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS

Ticker Exchange SIC # Website Latest Ticker
RNXT Nasdaq 3841 https://renovorx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for RenovoRx Inc

RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer - May 25th, 2023 12:30 pm
RenovoRx to Present at the LD Micro Invitational XIII Conference - May 24th, 2023 12:30 pm
RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights - May 15th, 2023 12:30 pm
RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride® Event - May 1st, 2023 12:30 pm
RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023 - Apr 28th, 2023 12:30 pm
RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors - Apr 27th, 2023 12:30 pm
RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida - Apr 14th, 2023 12:30 pm
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations - Apr 11th, 2023 12:30 pm
RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Mar 30th, 2023 4:20 pm
RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy - Mar 30th, 2023 12:30 pm
RenovoRx’s Principal Investigator of Phase III Clinical Trial Discusses Positive Interim Results on Patients with Locally Advanced Pancreatic Cancer on OncologyTube - Mar 22nd, 2023 1:00 pm
RenovoRx's Targeted Pancreatic Cancer Treatment Shows Positive Trend In Median Overall Survival Versus Standard Care - Mar 8th, 2023 5:26 pm
RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer - Mar 8th, 2023 1:30 pm
RenovoRX's Latest Innovative Technology Creates New Hope For Chemotherapy Patients - Mar 3rd, 2023 3:00 pm
RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone - Mar 2nd, 2023 1:30 pm
RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023 - Mar 1st, 2023 1:30 pm
RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023 - Jan 25th, 2023 1:30 pm
RenovoRx Reports Initial Results From Targeted Treatment For Pancreatic Cancer - Jan 18th, 2023 5:31 pm
RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment - Jan 18th, 2023 1:30 pm
Here's Why RenovoRx (NASDAQ:RNXT) Must Use Its Cash Wisely - Jan 11th, 2023 3:43 pm